Bristol CEO Sees Fruits Of Company Transformation


Salon Staff
January 11, 2012 12:36AM (UTC)

SAN FRANCISCO (AP) — Bristol-Myers Squibb Co.'s CEO says its transformation into a biopharmaceutical company has already brought five new product launches and soon could bring two more, for a new blood thinner and a diabetes drug that could be big sellers.

Lamberto Andreotti says the company's revamped pipeline also has added to revenue, and increased productivity has boosted profit.

Advertisement:

Meanwhile, Andreotti says the New York company is aiming to replace the current tough-to-endure mix of shots and pills for hepatitis C with a pill-only regimen that cures more patients and is easier to tolerate. That's behind Saturday's news that Bristol plans to buy hepatitis C drug developer Inhibitex Inc. for $2.5 billion.

Andreotti was speaking at the J.P. Morgan Global Healthcare Conference.


Salon Staff

MORE FROM Salon Staff



Fearless journalism
in your inbox every day

Sign up for our free newsletter

• • •